

April 19, 2022

Edward Smith
Chief Financial Officer
LAVA Therapeutics NV
Yalelaan 60
3584 CM Utrecht
The Netherlands

NV
Statement on Form F-3
2022

Re: LAVA Therapeutics
Registration
Filed April 12,
File No. 333-264246

Dear Mr. Smith:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Yale at 202-551-8776 with any questions.

Please contact Dorrie

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Peter Jaslow